BC Innovations | Nov 30, 2017
Emerging Company Profile

A versatile sponge

Treatment of sepsis and toxic shock requires eliminating bacterial toxins from the bloodstream, but it is often difficult to identify the causal pathogen and its products quickly enough to select a targeted therapy. Cellics Therapeutics...
BioCentury | Nov 17, 2017
Emerging Company Profile

New shot at sepsis

Critical Pressure Ltd. is developing a therapy for septic shock to combat hypotension more effectively than marketed vasopressors, and without their side effects. Sepsis is a systemic inflammatory response triggered by severe bacterial infection. Over...
BC Week In Review | Nov 17, 2017
Financial News

Sepsis play Critical Pressure raises L10M series A

Critical Pressure Ltd. (Cambridge, U.K.) raised £10 million ($13.1 million) on Nov. 15 in a series A round from Medicxi. The company is developing CPL001 to treat severe sepsis. The inhibitor of dimethylarginine dimethylaminohydrolase1 (DDAH1)...
BC Extra | Nov 15, 2017
Financial News

Sepsis play Critical Pressure raises £10M series A

Critical Pressure Ltd. (Cambridge, UK) raised £10 million ($13.1 million) in a series A round from Medicxi. The company is developing CPL001 to treat severe sepsis. The inhibitor of dimethylarginine dimethylaminohydrolase1 (DDAH1) is slated to...
Items per page:
1 - 4 of 4